{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:30:52Z","timestamp":1792603852905,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"am","delay-in-days":395,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.neurol.2022.12.003","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T07:22:17Z","timestamp":1671520937000},"page":"106-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Current treatments of spinal muscular atrophy in adults"],"prefix":"10.1016","volume":"179","author":[{"given":"P.","family":"Cintas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9630","key":"10.1016\/j.neurol.2022.12.003_bib0275","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","article-title":"Spinal muscular atrophy","volume":"371","author":"Lunn","year":"2008","journal-title":"Lancet."},{"issue":"5164","key":"10.1016\/j.neurol.2022.12.003_bib0280","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1126\/science.7910982","article-title":"De novo and inherited deletions of the 5q13 region in spinal muscular atrophies","volume":"264","author":"Melki","year":"1994","journal-title":"Science."},{"issue":"3","key":"10.1016\/j.neurol.2022.12.003_bib0285","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1006\/geno.1996.0147","article-title":"Structure and organization of the human survival motor neurone (SMN) gene","volume":"32","author":"B\u00fcrglen","year":"1996","journal-title":"Genomics."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet Med."},{"issue":"18","key":"10.1016\/j.neurol.2022.12.003_bib0295","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus Sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.neurol.2022.12.003_bib0300","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med."},{"issue":"14","key":"10.1016\/j.neurol.2022.12.003_bib0305","doi-asserted-by":"crossref","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","article-title":"Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes","volume":"95","author":"Wijngaarde","year":"2020","journal-title":"Neurology."},{"issue":"6","key":"10.1016\/j.neurol.2022.12.003_bib0310","doi-asserted-by":"crossref","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","article-title":"Ambulatory function in spinal muscular atrophy: age-related patterns of progression","volume":"13","author":"Montes","year":"2018","journal-title":"PLoS One."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0315","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nmd.2021.10.009","article-title":"Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes","volume":"32","author":"Coratti","year":"2022","journal-title":"Neuromuscul Disord."},{"issue":"5","key":"10.1016\/j.neurol.2022.12.003_bib0320","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.nmd.2017.01.018","article-title":"Disease impact on general well-being and therapeutic expectations of European type II and type III spinal muscular atrophy patients","volume":"27","author":"Rouault","year":"2017","journal-title":"Neuromuscul Disord."},{"issue":"5","key":"10.1016\/j.neurol.2022.12.003_bib0325","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.nmd.2021.01.012","article-title":"Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy","volume":"31","author":"Gusset","year":"2021","journal-title":"Neuromuscul Disord."},{"issue":"8","key":"10.1016\/j.neurol.2022.12.003_bib0330","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","article-title":"Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy","volume":"267","author":"Osmanovic","year":"2020","journal-title":"J Neurol."},{"issue":"8","key":"10.1016\/j.neurol.2022.12.003_bib0335","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1111\/ene.14902","article-title":"Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen","volume":"28","author":"Meyer","year":"2021","journal-title":"Eur J Neurol."},{"issue":"3","key":"10.1016\/j.neurol.2022.12.003_bib0340","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.neurol.2021.10.010","article-title":"Nusinersen treatment in adults with severe spinal muscular atrophy: a real-life retrospective observational cohort study","volume":"178","author":"Lefeuvre","year":"2022","journal-title":"Rev Neurol (Paris)."},{"key":"10.1016\/j.neurol.2022.12.003_bib0345","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","article-title":"Spinal muscular atrophy: in the challenge lies a solution","volume":"44","author":"Wirth","year":"2021","journal-title":"Trends Neurosci."},{"issue":"4","key":"10.1016\/j.neurol.2022.12.003_bib0350","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/MCB.26.4.1333-1346.2006","article-title":"Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron","volume":"26","author":"Singh","year":"2006","journal-title":"Mol Cell Biol."},{"issue":"4","key":"10.1016\/j.neurol.2022.12.003_bib0355","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.neurol.2022.12.003_bib0360","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00415-020-10223-9","article-title":"Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4","volume":"268","author":"De Wel","year":"2021","journal-title":"J Neurol."},{"issue":"11","key":"10.1016\/j.neurol.2022.12.003_bib0365","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"8","key":"10.1016\/j.neurol.2022.12.003_bib0370","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/acn3.51411","article-title":"Nusinersen in pediatric and adult patients with type III spinal muscular atrophy","volume":"8","author":"Pera","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0375","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis."},{"key":"10.1016\/j.neurol.2022.12.003_bib0380","doi-asserted-by":"crossref","first-page":"650532","DOI":"10.3389\/fneur.2021.650532","article-title":"Safety, tolerability, and effect of nusinersen in non-ambulatory adults with spinal muscular atrophy","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol."},{"key":"10.1016\/j.neurol.2022.12.003_bib0385","article-title":"Validation of motor and functional scales for the evaluation of adult patients with 5q spinal muscular atrophy","author":"V\u00e1zquez-Costa","year":"2022","journal-title":"Eur J Neurol."},{"key":"10.1016\/j.neurol.2022.12.003_bib0390","doi-asserted-by":"crossref","first-page":"650535","DOI":"10.3389\/fneur.2021.650535","article-title":"Safety, tolerability, and effect of nusinersen treatment in ambulatory adults with 5q-SMA","volume":"12","author":"Elsheikh","year":"2021","journal-title":"Front Neurol."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0395","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3233\/JND-210735","article-title":"Neurofilament levels in CSF and serum in an adult SMA cohort treated with nusinersen","volume":"9","author":"Rich","year":"2022","journal-title":"J Neuromuscul Dis."},{"issue":"8","key":"10.1016\/j.neurol.2022.12.003_bib0400","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/acn3.51625","article-title":"Biochemical and clinical biomarkers in adult SMA 3\u20134 patients treated with nusinersen for 22 months","volume":"9","author":"De Wel","year":"2022","journal-title":"Ann Clin Transl Neurol."},{"issue":"8","key":"10.1016\/j.neurol.2022.12.003_bib0405","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","article-title":"Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy","volume":"267","author":"Osmanovic","year":"2020","journal-title":"J Neurol."},{"key":"10.1016\/j.neurol.2022.12.003_bib0410","article-title":"Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts\u2019 study","author":"V\u00e1zquez-Costa","year":"2022","journal-title":"Eur J Neurol."},{"issue":"8","key":"10.1016\/j.neurol.2022.12.003_bib0415","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1111\/ene.14902","article-title":"Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen","volume":"28","author":"Meyer","year":"2021","journal-title":"Eur J Neurol."},{"issue":"6","key":"10.1016\/j.neurol.2022.12.003_bib0420","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1007\/s00415-021-10954-3","article-title":"Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen","volume":"269","author":"Bonanno","year":"2022","journal-title":"J Neurol."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0425","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00415-018-9124-0","article-title":"Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients","volume":"266","author":"Wurster","year":"2019","journal-title":"J Neurol."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0430","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/mus.26899","article-title":"Intrathecal delivery of nusinersen in individuals with complicated spines","volume":"62","author":"Cartwright","year":"2020","journal-title":"Muscle Nerve."},{"key":"10.1016\/j.neurol.2022.12.003_bib0435","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418803246","article-title":"Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy","volume":"11","author":"Stolte","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"10.1016\/j.neurol.2022.12.003_bib0440","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3174\/ajnr.A7009","article-title":"A systematic review of procedural complications from transforaminal lumbar puncture for intrathecal nusinersen administration in patients with spinal muscular atrophy","volume":"42","author":"Grayev","year":"2021","journal-title":"AJNR Am J Neuroradiol."},{"issue":"3","key":"10.1016\/j.neurol.2022.12.003_bib0445","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/15910199211032842","article-title":"Computed tomography-guided transforaminal lumbar puncture using local anesthesia and a straight 22-gauge spinal needle for intrathecal nusinersen in adults: findings in 77 procedures","volume":"28","author":"Cox","year":"2022","journal-title":"Interv Neuroradiol."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0450","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/neurintsurg-2020-016058","article-title":"Transforaminal intrathecal delivery of nusinersen for older children and adults with spinal muscular atrophy and complex spinal anatomy: an analysis of 200 consecutive injections","volume":"13","author":"Weaver","year":"2021","journal-title":"J Neurointerv Surg."},{"issue":"7","key":"10.1016\/j.neurol.2022.12.003_bib0455","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/ene.14245","article-title":"Computed-tomography-guided transforaminal intrathecal nusinersen injection in adults with spinal muscular atrophy type 2 and severe spinal deformity. Feasibility, safety and radiation exposure considerations","volume":"27","author":"Spiliopoulos","year":"2020","journal-title":"Eur J Neurol."},{"issue":"10","key":"10.1016\/j.neurol.2022.12.003_bib0460","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.nmd.2019.08.007","article-title":"Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: transforaminal versus conventional approach","volume":"29","author":"Bortolani","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"10.1016\/j.neurol.2022.12.003_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2019.01166","article-title":"Clinical implication of dosimetry of computed tomography- and fluoroscopy-guided intrathecal therapy with nusinersen in adult patients with spinal muscular atrophy","volume":"10","author":"Kizina","year":"2019","journal-title":"Front Neurol."},{"key":"10.1016\/j.neurol.2022.12.003_bib0470","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00234-019-02189-x","article-title":"Radiation exposure of image-guided intrathecal administration of nusinersen to adult patients with spinal muscular atrophy","volume":"61","author":"Oldenburg","year":"2019","journal-title":"Neuroradiology."},{"issue":"12","key":"10.1016\/j.neurol.2022.12.003_bib0475","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1007\/s00415-021-10569-8","article-title":"Nusinersen treatment in adult patients with spinal muscular atrophy: a safety analysis of laboratory parameters","volume":"268","author":"Stolte","year":"2021","journal-title":"J Neurol."},{"issue":"6","key":"10.1016\/j.neurol.2022.12.003_bib0480","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/acn3.51562","article-title":"Scientific rationale for a higher dose of nusinersen","volume":"9","author":"Finkel","year":"2022","journal-title":"Ann Clin Transl Neurol."},{"issue":"5","key":"10.1016\/j.neurol.2022.12.003_bib0485","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/13543784.2022.2056836","article-title":"Risdiplam: an investigational survival motor neuron 2 (SMN2) splicing modifier for spinal muscular atrophy (SMA)","volume":"31","author":"Markati","year":"2022","journal-title":"Expert Opin Investig Drugs."},{"issue":"10","key":"10.1016\/j.neurol.2022.12.003_bib0490","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1056\/NEJMoa2009965","article-title":"Risdiplam in type 1 spinal muscular atrophy","volume":"384","author":"Baranello","year":"2021","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.neurol.2022.12.003_bib0495","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2102047","article-title":"Risdiplam-treated infants with type 1 spinal muscular atrophy versus historical controls","volume":"385","author":"Darras","year":"2021","journal-title":"N Engl J Med."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0500","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(21)00367-7","article-title":"Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"21","author":"Mercuri","year":"2022","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0505","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13023-022-02420-8","article-title":"Risdiplam Compassionate Use Program Group. Short-term safety results from compassionate use of risdiplam in patients with spinal muscular atrophy in Germany","volume":"17","author":"Hahn","year":"2022","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0510","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/acn3.51239","article-title":"Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy","volume":"8","author":"Sergott","year":"2021","journal-title":"Ann Clin Transl Neurol."},{"issue":"18","key":"10.1016\/j.neurol.2022.12.003_bib0515","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.neurol.2022.12.003_bib0520","doi-asserted-by":"crossref","DOI":"10.1089\/hum.2022.054","article-title":"Prevalence of anti-adeno-associated virus serotype 9 antibodies in adult patients with spinal muscular atrophy","author":"Stolte","year":"2022","journal-title":"Hum Gene Ther."},{"issue":"1","key":"10.1016\/j.neurol.2022.12.003_bib0525","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/jmg.2007.051177","article-title":"Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells","volume":"45","author":"Angelozzi","year":"2008","journal-title":"J Med Genet."},{"issue":"7","key":"10.1016\/j.neurol.2022.12.003_bib0530","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.nmd.2019.04.003","article-title":"Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II","volume":"29","author":"Frongia","year":"2019","journal-title":"Neuromuscul Disord."},{"issue":"5","key":"10.1016\/j.neurol.2022.12.003_bib0535","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/jmedgenet-2018-105482","article-title":"Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol","volume":"56","author":"Tiziano","year":"2019","journal-title":"J Med Genet."},{"issue":"2","key":"10.1016\/j.neurol.2022.12.003_bib0540","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s13311-020-01004-3","article-title":"Reldesemtiv in patients with spinal muscular atrophy: a phase 2 hypothesis-generating study","volume":"18","author":"Rudnicki","year":"2021","journal-title":"Neurotherapeutics."}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872200844X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872200844X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:46:02Z","timestamp":1758519962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003537872200844X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":54,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S003537872200844X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2022.12.003","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current treatments of spinal muscular atrophy in adults","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2022.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}